Oscar Ortega
Family Medicine · Tacoma, WANPI 1225192784
Payments from drug & device makers
Across 171 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Boehringer Ingelheim$310
- GSK$186
- Neurocrine Biosciences, Inc.$177
- Pfizer$170
- AstraZeneca$163
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,332100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $1,282 |
| Boehringer Ingelheim | 15 | $310 |
| GSK | 7 | $186 |
| Neurocrine Biosciences, Inc. | 6 | $177 |
| Pfizer | 8 | $170 |
| AstraZeneca | 9 | $163 |
| Kowa Pharmaceuticals America, Inc. | 7 | $139 |
| Nestle Healthcare Nutrition Inc. | 5 | $108 |
| Otsuka America Pharmaceutical, Inc. | 5 | $97 |
| Lilly USA, LLC | 4 | $92 |
| Amgen | 4 | $89 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $80 |
| Daiichi Sankyo Inc. | 3 | $65 |
| Orexo US, Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Zyla Life Sciences, Inc. | 2 | $31 |
| Indivior Inc. | 2 | $30 |
| Nevro Corp. | 1 | $25 |
| Mayne Pharma Commercial LLC | 1 | $24 |
| Exact Sciences | 1 | $22 |
| Alkermes, Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| Circassia Inc. | 1 | $15 |
How this compares
$3,332 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 13 | $10,154 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 43 | $8,988 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,095 |
| EliquisApixaban | 15 | $5,116 |
| Gabapentin | 49 | $902 |
| Ropinirole Hcl | 11 | $634 |
| Buprenorphine Hcl | 14 | $447 |
| Atorvastatin Calcium | 49 | $376 |
| Tamsulosin Hcl | 16 | $321 |
| Quetiapine Fumarate | 27 | $314 |
| Duloxetine Hcl | 21 | $305 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $293 |
| Metformin Hcl | 37 | $272 |
| Finasteride | 13 | $167 |
| Buspirone Hcl | 16 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $310 | $10,15413 claims |
| GSKAnoro Ellipta | $186 | $7,09516 claims |
| PfizerEliquis | $170 | $5,11615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Tacoma
- James RoscettiTacoma$184K
- Marse McNaughtonTacoma$24K
- Benjamin DyTacoma$15K
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.